Deutsche Bank AG lowered shares of H. Lundbeck A/S- (NASDAQ:HLUYY) from a hold rating to a sell rating in a research report sent to investors on Friday, Marketbeat reports.

A number of other equities analysts have also recently commented on the stock. Zacks Investment Research cut shares of H. Lundbeck A/S- from a buy rating to a hold rating in a research note on Monday, July 17th. Jefferies Group LLC cut shares of H. Lundbeck A/S- from a buy rating to a hold rating in a research note on Tuesday, April 11th.

Shares of H. Lundbeck A/S- (NASDAQ:HLUYY) opened at 59.97 on Friday. H. Lundbeck A/S- has a 12-month low of $31.00 and a 12-month high of $61.72. The stock has a market capitalization of $11.83 billion and a price-to-earnings ratio of 46.92. The stock’s 50 day moving average is $57.24 and its 200-day moving average is $49.07.

ILLEGAL ACTIVITY WARNING: This report was published by Watch List News and is the sole property of of Watch List News. If you are viewing this report on another publication, it was copied illegally and reposted in violation of international copyright & trademark legislation. The original version of this report can be read at https://www.watchlistnews.com/h-lundbeck-as-nasdaqhluyy-downgraded-to-sell-at-deutsche-bank-ag/1465499.html.

H. Lundbeck A/S- Company Profile

H Lundbeck A/S is a Denmark-based company active in the pharmaceuticals industry. It is engaged in the research, development, manufacture and marketing of pharmaceuticals for the treatment of brain disorders, such as Alzheimer’s disease, Bipolar disorder, depression, epilepsy, Huntington’s disease, Parkinson’s disease and schizophrenia.

Receive News & Ratings for H. Lundbeck A/S- Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for H. Lundbeck A/S- and related companies with Analyst Ratings Network's FREE daily email newsletter.